OR WAIT 15 SECS
Fujifilm Irvine Scientific has announced plans to open a third manufacturing facility in Tilburg, The Netherlands.
Fujifilm Irvine Scientific has announced plans to open a third manufacturing facility in Tilburg, The Netherlands, supporting the company’s commitment to accelerate development in bioproduction as well as cell- and gene-therapy markets.
The new facility, which will add to the company’s already existing sites in the United States and Japan, will form part of Fujifilm Manufacturing Europe’s center and will support cGMP manufacturing of annual component-free, dry powder media, liquid media, and downstream bioprocessing liquid. Work on the new facility has already begun and is expected to be commissioned in the second half of 2021.
“The biopharmaceutical market is growing at a high rate, and cell therapies are moving into clinical trials and commercialization at fast pace. The company’s current capacity is >1 million kg/year of dry powder, but it is imperative that we exceed production requirements of customers worldwide, as well as meet our European customer demand for regional support,” said Yutaka Yamaguchi, CEO, Fujifilm Irvine Scientific, in a press statement. “Building a third, world-class cGMP manufacturing facility to serve as a European hub will enable us to better provide customers with rapid, reliable supply of products.”
Source: Fujifilm Irvine Scientific